Infant Bacterial Therapeutics

Infant Bacterial Therapeutics is a clinical-stage pharmaceutical company with the vision of developing drugs that impact the infant microbiome to prevent or treat rare diseases affecting infants. IBT is developing the candidate drug IBP-9414 for the prevention of NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain naturally found in breast milk.